Drugs / NBP607
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03893669 | Sep → Oct 2012 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02621177 | Nov 2013 → Mar 2014 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02344134 | Sep → Nov 2013 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBP607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02344134 ↗ |
| Known as | Trivalent Inactivated Cell-Culture Influenza Vaccine | “NBP607(Trivalent Inactivated Cell-Culture Influenza Vaccine)” NCT03893669 ↗ |
| Modality | Vaccine | “a novel cell culture-derived inactivated, subunit, trivalent influenza vaccine (NBP607, SK Chemicals, Seongnam, Korea)” PMID 26314625 ↗ Aug 2015 |
| Route | Intramuscular | “0.5 mL, intramuscular, a single dose” NCT02344134 ↗ |